NFKB1 and aneurysmal bone cyst: In addition, MyD88 mutations occur in > 30% of ABC DLBCL cases and activate both NF-κB and JAK–STAT signaling pathways [57], both of which participate in anti-apoptosis, cell survival and chemoresistance [49, 58, 59].